KURA
Kura Oncology, Inc.
Price Chart
Latest Quote
$10.86
-0.03 (-0.28%)
Current Price
| Previous Close | $10.89 |
| Open | $10.64 |
| Day High | $10.99 |
| Day Low | $10.50 |
| Volume | 794,186 |
Stock Information
| Shares Outstanding | 88.77M |
| Total Debt | $24.27M |
| Cash Equivalents | $580.82M |
| Revenue | $71.64M |
| Net Income | $-294.57M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $964.09M |
| EPS (TTM) | $-3.35 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $407.54M |
| Sales | $71.64M |
| Income | $-294.57M |
| Book/sh | $1.22 |
| Cash/sh | $6.54 |
| Employees | 260 |
Financial Ratios
| Quick Ratio | 5.86 |
| Current Ratio | 6.15 |
| Debt/Eq | 22.50 |
Returns & Margins
| ROA | -28.44% |
| ROE | -124.74% |
| Gross Margin | -263.88% |
| Operating Margin | -431.51% |
Ownership
| Insider Ownership | 1.43% |
| Institutional Ownership | 96.85% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.18 |
| P/S | 13.46 |
| P/B | 8.94 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $31.17 |
Technical Indicators
| SMA20 | $11.01 |
| SMA50 | $10.09 |
| SMA200 | $9.63 |
| RSI | 49.48 |
| ATR | 0.5269 |
| Shares Float | 70.42M |
| Short Float | 17.45% |
| Short Ratio | 7.94 |
| Volatility | 0.35 |
| Rel Volume | 0.46 |
Performance History
| Week | -5.15% |
| Month | +15.53% |
| Quarter | +21.48% |
| 6 Months | +16.03% |
| YTD | +5.08% |
| Year | +70.22% |
| 3 Years | +5.44% |
| 5 Years | -45.37% |
| 10 Years | +147.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $10.86 | 794,186 |
| 2026-07-16 | $10.89 | 939,000 |
| 2026-07-15 | $11.33 | 1,152,700 |
| 2026-07-14 | $11.24 | 1,591,600 |
| 2026-07-13 | $10.91 | 1,579,500 |
| 2026-07-10 | $11.45 | 1,338,800 |
| 2026-07-09 | $12.08 | 1,414,400 |
| 2026-07-08 | $12.12 | 1,918,800 |
| 2026-07-07 | $11.99 | 3,811,800 |
| 2026-07-06 | $11.04 | 1,350,900 |
| 2026-07-02 | $11.10 | 1,888,300 |
| 2026-07-01 | $10.78 | 2,086,700 |
| 2026-06-30 | $10.97 | 1,529,300 |
| 2026-06-29 | $10.97 | 1,165,400 |
| 2026-06-26 | $10.90 | 5,273,100 |
| 2026-06-25 | $10.36 | 1,510,500 |
| 2026-06-24 | $10.62 | 1,303,800 |
| 2026-06-23 | $10.38 | 1,112,900 |
| 2026-06-22 | $10.36 | 1,386,200 |
| 2026-06-18 | $9.93 | 1,700,100 |
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
đ° Latest News
Does Kura Oncologyâs (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story?
Simply Wall St. âĸ 2026-07-07T22:09:03Z
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
Insider Monkey âĸ 2026-06-30T13:06:47Z
How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions
Simply Wall St. âĸ 2026-06-06T08:07:10Z
Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates
Simply Wall St. âĸ 2026-05-17T13:22:33Z
Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Trimming Their Forecasts
Simply Wall St. âĸ 2026-05-15T13:10:30Z
Kura Oncology, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-13T12:30:00Z
Kura Oncology Inc (KURA) Q1 2026 Earnings Call Highlights: Strong KOMZIFTI Launch Amid Rising ...
GuruFocus.com âĸ 2026-05-13T05:02:19ZKura Oncology Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T01:09:07Z
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-12T21:15:01Z
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T21:55:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $57,000 | $0 | $0 | - |
| Cost Of Revenue | $57,000 | $0 | $0 | - |
| Total Revenue | $67,482,000 | $53,883,000 | $0 | $0 |
| Operating Revenue | $67,482,000 | $53,883,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,512,000 | $1,619,000 | $1,549,000 | $229,000 |
| Total Expenses | $371,113,000 | $247,078,000 | $165,804,000 | $139,865,000 |
| Net Non Operating Interest Income Expense | $25,262,000 | $21,230,000 | $13,173,000 | $4,025,000 |
| Interest Expense Non Operating | $1,512,000 | $1,619,000 | $1,549,000 | $229,000 |
| Operating Expense | $371,056,000 | $247,078,000 | $165,804,000 | $139,865,000 |
| General And Administrative Expense | $119,982,000 | $77,111,000 | $50,569,000 | $47,053,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-278,666,000 | $-173,983,000 | $-152,631,000 | $-135,840,000 |
| Net Interest Income | $25,262,000 | $21,230,000 | $13,173,000 | $4,025,000 |
| Interest Income | $26,774,000 | $22,849,000 | $14,722,000 | $4,254,000 |
| Normalized Income | $-278,666,000 | $-173,983,000 | $-152,631,000 | $-135,840,000 |
| Net Income From Continuing And Discontinued Operation | $-278,666,000 | $-173,983,000 | $-152,631,000 | $-135,840,000 |
| Total Operating Income As Reported | $-303,631,000 | $-193,195,000 | $-165,804,000 | - |
| Net Income Common Stockholders | $-278,666,000 | $-173,983,000 | $-152,631,000 | $-135,840,000 |
| Net Income | $-278,666,000 | $-173,983,000 | $-152,631,000 | $-135,840,000 |
| Net Income Including Noncontrolling Interests | $-278,666,000 | $-173,983,000 | $-152,631,000 | $-135,840,000 |
| Net Income Continuous Operations | $-278,666,000 | $-173,983,000 | $-152,631,000 | $-135,840,000 |
| Pretax Income | $-278,369,000 | $-171,965,000 | $-152,631,000 | $-135,840,000 |
| Interest Income Non Operating | $26,774,000 | $22,849,000 | $14,722,000 | $4,254,000 |
| Operating Income | $-303,631,000 | $-193,195,000 | $-165,804,000 | $-139,865,000 |
| Gross Profit | $67,425,000 | $53,883,000 | $0 | - |
| Per Share | ||||
| Diluted EPS | $-3.18 | $-2.02 | $-2.08 | $-2.03 |
| Basic EPS | $-3.18 | $-2.02 | $-2.08 | $-2.03 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-275,825,000 | $-169,498,000 | $-150,233,000 | $-134,852,000 |
| Reconciled Depreciation | $1,032,000 | $848,000 | $849,000 | $759,000 |
| EBITDA (Bullshit earnings) | $-275,825,000 | $-169,498,000 | $-150,233,000 | $-134,852,000 |
| EBIT | $-276,857,000 | $-170,346,000 | $-151,082,000 | $-135,611,000 |
| Diluted Average Shares | $87,676,000 | $86,161,000 | $73,229,000 | $66,990,000 |
| Basic Average Shares | $87,676,000 | $86,161,000 | $73,229,000 | $66,990,000 |
| Diluted NI Availto Com Stockholders | $-278,666,000 | $-173,983,000 | $-152,631,000 | $-135,840,000 |
| Tax Provision | $297,000 | $2,018,000 | $0 | $0 |
| Research And Development | $251,074,000 | $169,967,000 | $115,235,000 | $92,812,000 |
| Selling General And Administration | $119,982,000 | $77,111,000 | $50,569,000 | $47,053,000 |
| Other Gand A | $119,982,000 | $77,111,000 | $50,569,000 | $47,053,000 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $174,135,000 | $413,640,000 | $397,273,000 | $420,278,000 |
| Total Assets | $738,363,000 | $760,159,000 | $448,935,000 | $456,306,000 |
| Total Non Current Assets | $29,700,000 | $15,330,000 | $16,454,000 | $9,880,000 |
| Other Non Current Assets | $14,543,000 | $7,845,000 | $7,602,000 | $3,498,000 |
| Current Assets | $708,663,000 | $744,829,000 | $432,481,000 | $446,426,000 |
| Other Current Assets | $32,206,000 | $15,374,000 | $8,524,000 | $8,441,000 |
| Inventory | $413,000 | $0 | - | - |
| Receivables | $8,804,000 | $2,060,000 | - | - |
| Accounts Receivable | $8,804,000 | $2,060,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $667,240,000 | $727,395,000 | $423,957,000 | $437,985,000 |
| Cash And Cash Equivalents | $149,099,000 | $224,462,000 | $37,318,000 | $51,802,000 |
| Cash Equivalents | - | $200,024,000 | $13,590,000 | $47,834,000 |
| Cash Financial | - | $24,438,000 | $23,728,000 | $3,968,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $20,457,000 | $16,594,000 | $17,200,000 | $14,024,000 |
| Long Term Debt And Capital Lease Obligation | $19,180,000 | $12,106,000 | $15,694,000 | $11,706,000 |
| Long Term Debt | $9,711,000 | $6,916,000 | $9,332,000 | $9,158,000 |
| Current Debt And Capital Lease Obligation | $1,277,000 | $4,488,000 | $1,506,000 | $2,318,000 |
| Current Debt | - | $2,607,000 | - | - |
| Other Current Borrowings | - | $2,607,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $564,228,000 | $346,519,000 | $51,662,000 | $36,028,000 |
| Total Non Current Liabilities Net Minority Interest | $447,254,000 | $267,807,000 | $16,399,000 | $11,971,000 |
| Other Non Current Liabilities | $3,165,000 | $1,795,000 | $705,000 | $265,000 |
| Non Current Deferred Liabilities | $424,909,000 | $253,906,000 | $0 | - |
| Current Liabilities | $116,974,000 | $78,712,000 | $35,263,000 | $24,057,000 |
| Current Deferred Liabilities | $48,983,000 | $24,271,000 | $0 | - |
| Payables And Accrued Expenses | $44,342,000 | $32,445,000 | $20,604,000 | $11,439,000 |
| Payables | $5,256,000 | $3,530,000 | $2,300,000 | $1,533,000 |
| Total Tax Payable | $239,000 | $2,061,000 | $0 | - |
| Income Tax Payable | $239,000 | $2,061,000 | $0 | - |
| Accounts Payable | $5,017,000 | $1,469,000 | $2,300,000 | $1,533,000 |
| Equity | ||||
| Common Stock Equity | $174,135,000 | $413,640,000 | $397,273,000 | $420,278,000 |
| Total Equity Gross Minority Interest | $174,135,000 | $413,640,000 | $397,273,000 | $420,278,000 |
| Stockholders Equity | $174,135,000 | $413,640,000 | $397,273,000 | $420,278,000 |
| Gains Losses Not Affecting Retained Earnings | $1,024,000 | $764,000 | $-1,271,000 | $-8,032,000 |
| Other Equity Adjustments | $1,024,000 | $764,000 | $-1,271,000 | $-8,032,000 |
| Retained Earnings | $-1,174,088,000 | $-895,422,000 | $-721,439,000 | $-568,808,000 |
| Other | ||||
| Ordinary Shares Number | $87,855,000 | $78,229,000 | $74,350,000 | $68,314,000 |
| Share Issued | $87,855,000 | $78,229,000 | $74,350,000 | $68,314,000 |
| Tangible Book Value | $174,135,000 | $413,640,000 | $397,273,000 | $420,278,000 |
| Invested Capital | $183,846,000 | $423,163,000 | $406,605,000 | $429,436,000 |
| Working Capital | $591,689,000 | $666,117,000 | $397,218,000 | $422,369,000 |
| Capital Lease Obligations | $10,746,000 | $7,071,000 | $7,868,000 | $4,866,000 |
| Total Capitalization | $183,846,000 | $420,556,000 | $406,605,000 | $429,436,000 |
| Additional Paid In Capital | $1,347,190,000 | $1,308,290,000 | $1,119,976,000 | $997,111,000 |
| Capital Stock | $9,000 | $8,000 | $7,000 | $7,000 |
| Common Stock | $9,000 | $8,000 | $7,000 | $7,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $424,909,000 | $253,906,000 | $0 | - |
| Long Term Capital Lease Obligation | $9,469,000 | $5,190,000 | $6,362,000 | $2,548,000 |
| Current Deferred Revenue | $48,983,000 | $24,271,000 | $0 | - |
| Current Capital Lease Obligation | $1,277,000 | $1,881,000 | $1,506,000 | $2,318,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $22,372,000 | $17,508,000 | $13,153,000 | $10,300,000 |
| Current Accrued Expenses | $39,086,000 | $28,915,000 | $18,304,000 | $9,906,000 |
| Net PPE | $15,157,000 | $7,485,000 | $8,852,000 | $6,382,000 |
| Accumulated Depreciation | $-2,900,000 | $-3,275,000 | $-2,452,000 | $-1,603,000 |
| Gross PPE | $18,057,000 | $10,760,000 | $11,304,000 | $7,985,000 |
| Leases | $6,919,000 | $1,743,000 | $1,543,000 | $1,543,000 |
| Other Properties | $7,302,000 | $5,803,000 | $6,993,000 | $3,842,000 |
| Machinery Furniture Equipment | $3,836,000 | $3,214,000 | $2,768,000 | $2,600,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $518,141,000 | $502,933,000 | $386,639,000 | $386,183,000 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-70,696,000 | $133,845,000 | $-124,992,000 | $-110,688,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-64,058,000 | $134,317,000 | $-124,824,000 | $-110,062,000 |
| Cash Flow From Continuing Operating Activities | $-64,058,000 | $134,317,000 | $-124,824,000 | $-110,062,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-6,638,000 | $-472,000 | $-168,000 | $-626,000 |
| Investing Cash Flow | $-13,098,000 | $-101,590,000 | $15,557,000 | $32,627,000 |
| Cash Flow From Continuing Investing Activities | $-13,098,000 | $-101,590,000 | $15,557,000 | $32,627,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $145,813,000 | $93,577,000 | $24,721,000 |
| Financing Cash Flow | $1,793,000 | $154,417,000 | $94,783,000 | $38,565,000 |
| Cash Flow From Continuing Financing Activities | $1,793,000 | $154,417,000 | $94,783,000 | $38,565,000 |
| Net Common Stock Issuance | $0 | $145,813,000 | $93,577,000 | $24,721,000 |
| Common Stock Issuance | $0 | $145,813,000 | $93,577,000 | $24,721,000 |
| Net Other Financing Charges | - | - | - | $-575,000 |
| Other | ||||
| Interest Paid Supplemental Data | $998,000 | $1,096,000 | $1,064,000 | $73,000 |
| End Cash Position | $149,099,000 | $224,462,000 | $37,318,000 | $51,802,000 |
| Beginning Cash Position | $224,462,000 | $37,318,000 | $51,802,000 | $90,672,000 |
| Changes In Cash | $-75,363,000 | $187,144,000 | $-14,484,000 | $-38,870,000 |
| Proceeds From Stock Option Exercised | $1,793,000 | $8,604,000 | $1,206,000 | $4,419,000 |
| Net Investment Purchase And Sale | $-6,460,000 | $-101,118,000 | $15,725,000 | $33,253,000 |
| Sale Of Investment | $755,128,000 | $557,930,000 | $425,549,000 | $303,908,000 |
| Purchase Of Investment | $-761,588,000 | $-659,048,000 | $-409,824,000 | $-270,655,000 |
| Net PPE Purchase And Sale | $-6,638,000 | $-472,000 | $-168,000 | $-626,000 |
| Purchase Of PPE | $-6,638,000 | $-472,000 | $-168,000 | $-626,000 |
| Change In Working Capital | $184,441,000 | $286,173,000 | $7,819,000 | $-2,982,000 |
| Change In Other Working Capital | $195,715,000 | $278,178,000 | - | - |
| Change In Other Current Liabilities | $1,043,000 | $758,000 | $137,000 | $184,000 |
| Change In Other Current Assets | $-6,363,000 | $947,000 | $-685,000 | $571,000 |
| Change In Payables And Accrued Expense | $17,153,000 | $15,200,000 | $10,327,000 | $-802,000 |
| Change In Accrued Expense | $12,654,000 | $16,827,000 | $11,251,000 | - |
| Change In Payable | $4,499,000 | $-1,627,000 | $-924,000 | $-802,000 |
| Change In Account Payable | $4,499,000 | $-1,627,000 | $-924,000 | $-802,000 |
| Change In Prepaid Assets | $-15,950,000 | $-6,850,000 | $-1,960,000 | $-2,935,000 |
| Change In Inventory | $-413,000 | $0 | $0 | - |
| Change In Receivables | $-6,744,000 | $-2,060,000 | $0 | - |
| Changes In Account Receivables | $-6,744,000 | $-2,060,000 | $0 | - |
| Other Non Cash Items | $515,000 | $523,000 | $477,000 | $73,000 |
| Stock Based Compensation | $37,108,000 | $33,897,000 | $28,082,000 | $26,318,000 |
| Amortization Of Securities | $-8,488,000 | $-13,141,000 | $-9,420,000 | $1,610,000 |
| Depreciation Amortization Depletion | $1,032,000 | $848,000 | $849,000 | $759,000 |
| Depreciation And Amortization | $1,032,000 | $848,000 | $849,000 | $759,000 |
| Depreciation | $1,032,000 | $848,000 | $849,000 | $759,000 |
| Net Income From Continuing Operations | $-278,666,000 | $-173,983,000 | $-152,631,000 | $-135,840,000 |
| Issuance Of Debt | - | $0 | $0 | $10,000,000 |
| Net Issuance Payments Of Debt | - | $0 | $0 | $10,000,000 |
| Net Long Term Debt Issuance | - | $0 | $0 | $10,000,000 |
| Long Term Debt Issuance | - | $0 | $0 | $10,000,000 |
| Repayment Of Debt | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
Fetched: 2026-07-15